Literature DB >> 11384233

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.

J H Chan1, J S Hong, R N Hunter , G F Orr, J R Cowan, D B Sherman, S M Sparks, B E Reitter, C W Andrews , R J Hazen, M St Clair, L R Boone, R G Ferris, K L Creech, G B Roberts, S A Short, K Weaver, R J Ott, J Ren, A Hopkins, D I Stuart, D K Stammers.   

Abstract

A series of 2-amino-5-arylthiobenzonitriles (1) was found to be active against HIV-1. Structural modifications led to the sulfoxides (2) and sulfones (3). The sulfoxides generally showed antiviral activity against HIV-1 similar to that of 1. The sulfones, however, were the most potent series of analogues, a number having activity against HIV-1 in the nanomolar range. Structural-activity relationship (SAR) studies suggested that a meta substituent, particularly a meta methyl substituent, invariably increased antiviral activities. However, optimal antiviral activities were manifested by compounds where both meta groups in the arylsulfonyl moiety were substituted and one of the substituents was a methyl group. Such a disubstitution led to compounds 3v, 3w, 3x, and 3y having IC50 values against HIV-1 in the low nanomolar range. When gauged for their broad-spectrum antiviral activity against key non-nucleoside reverse transcriptase inhibitor (NNRTI) related mutants, all the di-meta-substituted sulfones 3u-z and the 2-naphthyl analogue 3ee generally showed single-digit nanomolar activity against the V106A and P236L strains and submicromolar to low nanomolar activity against strains E138K, V108I, and Y188C. However, they showed a lack of activity against the K103N and Y181C mutant viruses. The elucidation of the X-ray crystal structure of the complex of 3v (739W94) in HIV-1 reverse transcriptase showed an overlap in the binding domain when compared with the complex of nevirapine in HIV-1 reverse transcriptase. The X-ray structure allowed for the rationalization of SAR data and potencies of the compounds against the mutants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384233     DOI: 10.1021/jm0004906

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

2.  Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining.

Authors:  Jose Luis Medina-Franco; Alexander Golbraikh; Scott Oloff; Rafael Castillo; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2005-04       Impact factor: 3.686

3.  Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.

Authors:  Gabriela Barreiro; Cristiano R W Guimarães; Ivan Tubert-Brohman; Theresa M Lyons; Julian Tirado-Rives; William L Jorgensen
Journal:  J Chem Inf Model       Date:  2007-10-20       Impact factor: 4.956

4.  Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.

Authors:  Norikazu Sakakibara; Masanori Baba; Mika Okamoto; Masaaki Toyama; Yosuke Demizu; Takashi Misawa; Masaaki Kurihara; Kohji Irie; Yoshihisa Kato; Tokumi Maruyama
Journal:  Antivir Chem Chemother       Date:  2015-02

5.  Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.

Authors:  Janice D Pata; William G Stirtan; Steven W Goldstein; Thomas A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design.

Authors:  Joseph D Bauman; Kalyan Das; William C Ho; Mukta Baweja; Daniel M Himmel; Arthur D Clark; Deena A Oren; Paul L Boyer; Stephen H Hughes; Aaron J Shatkin; Eddy Arnold
Journal:  Nucleic Acids Res       Date:  2008-08-01       Impact factor: 16.971

Review 7.  N-Pyrrylarylsulfones with High Therapeutic Potential.

Authors:  Valeria Famiglini; Sabrina Castellano; Romano Silvestri
Journal:  Molecules       Date:  2017-03-09       Impact factor: 4.411

8.  Site-Selective Suzuki-Miyaura and Sonogashira Cross Coupling Reactions of the Bis(triflate) of 2,4'-Bis(hydroxy)diphenyl Sulfone.

Authors:  Rasheed Ahmad Khera; Asad Ali; Munawar Hussain; Muhammad Farooq Ibad; Alexander Villinger; Peter Langer
Journal:  ChemCatChem       Date:  2012-02-01       Impact factor: 5.686

Review 9.  Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Valeria Famiglini; Romano Silvestri
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

10.  First synthesis of 4-(arylsulfonyl)phenols by regioselective [3+3] cyclocondensations of 1,3-bis(silyloxy)-1,3-butadienes with 2-arylsulfonyl-3-ethoxy-2-en-1-ones.

Authors:  Abdolmajid Riahi; Mohanad Shkoor; Olumide Fatunsin; Mathias Lubbe; Helmut Reinke; Peter Langer
Journal:  Tetrahedron Lett       Date:  2008-11-01       Impact factor: 2.415

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.